



LABORATORY REPORT

Example Client, XYZ123
1234 Warde Road
Ann Arbor MI 48108

EXAMPLE, REPORT W
WX0000003827 M 07/08/1978 45 Y

Molecular

Collected: 08/25/2023 12:01 Received: 08/25/2023 12:01

Table with 6 columns: Test Name, Result, Flag, Ref-Ranges, Units, Site. Row 1: BCR-ABL1 Minor (p190) Rearrangement, Quantitative PCR. Row 2: p190 Result, Not detected, see below, WMRL. Row 3: p190 % Ratio, N/A, see below, %, WMRL. Row 4: BCR-ABL1 Minor (p190) Comment, see below, see below, WMRL.

The e1a2 transcript for the p190 product was not detected. The test does not monitor e13a2, e14a2, or other fusion transcripts resulting from t(9;22). This test is not intended for the diagnosis of CML.

This test was performed using the QuantideX® qPCR BCR-ABL minor Kit (Assuragen). The QuantideX® qPCR BCR-ABL minor Kit is an in vitro nucleic acid amplification test for the quantitation of BCRABL1 and ABL1 transcripts in total RNA from whole blood of diagnosed t(9;22) positive Chronic Myeloid Leukemia (CML) patients expressing BCR-ABL1 fusion transcript type e1a2. The QuantideX® qPCR BCR-ABL minor Kit is a reverse transcription-quantitative PCR performed on the Applied Biosystems 7500 Fast Dx Real-Time PCR Instrument and is intended to measure BCR-ABL1 to ABL1, expressed as a percent ratio (BCR-ABL1 to ABL1) in t(9;22) positive CML patients during monitoring of treatment with Tyrosine Kinase Inhibitors (TKIs). The test does not monitor e13a2, e14a2, or other fusion transcripts resulting from t(9;22).

Performing Site:

WMRL: WARDE MEDICAL LABORATORY 300 West Textile Road Ann Arbor MI 48108

Reported Date: 2023.08.25 12:01 BCRMN

LAB: L - LOW, H - HIGH, AB - ABNORMAL, C - CRITICAL, . - NOT TESTED

F225000010
WX0000003827

Ordered By: KAJAL SITWALA, MD, PhD
WX000000000002365

Kajal V. Sitwala, MD, PhD - Medical Director
Form: MM RL1

Printed D&T: 08/25/23 12:01

PAGE 1 OF 1